Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMVGMNC)

Drug Name

MK-0616 Drug Info

Synonyms

MK0616; MK-0616; GTPL12689; GLXC-27059; PCSK9 macrocyclic peptide inhibitor MK-0616

Indication

Disease Entry	ICD 11	Status	REF
Hypercholesterolaemia	5C80.0	Phase 2	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proprotein convertase subtilisin/kexin type 9 (PCSK9)	TTBRG7E	PCSK9_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Hypercholesterolaemia

ICD Disease Classification

5C80.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Proprotein convertase subtilisin/kexin type 9 (PCSK9)	DTT	PCSK9	4.82E-02	-0.07	-0.3

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT05261126) A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia. U.S.National Institutes of Health.
2	Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol. 2023 Apr 25;81(16):1553-1564.